Endometriosis Blood Test Breakthrough

A new study says a simple blood test can spot endometriosis with over 95% accuracy — and for the 190 million women who wait an average of seven to ten years for a diagnosis, that number is either a breakthrough or another false dawn.

Story Snapshot

Researchers found that women with endometriosis have a distinct hormone pattern in their blood, including high levels of a specific androgen called 11-ketotestosterone.
The study used blood samples from 159 women and reported the test correctly identified endometriosis in over 95% of cases.
A separate commercial blood test called HerResolve, made by HerAnova Lifesciences, found cases missed by ultrasound and MRI — but its sensitivity was only 80%.
A major Cochrane review of 27 studies covering more than 3,400 women concluded that no blood test has yet been accurate enough to replace surgery for diagnosis.

Why This Finding Matters So Much to So Many Women

Endometriosis affects roughly 1 in 10 women of reproductive age. The condition causes tissue similar to the uterine lining to grow outside the uterus. It triggers chronic pain, heavy periods, and often infertility. Despite how common it is, the only way doctors can confirm the diagnosis today is through laparoscopic surgery — a procedure that requires anesthesia and recovery time. The average woman waits seven to ten years just to get that answer.

That delay is not just frustrating. It causes real harm. Women spend years being told their pain is normal, cycling through wrong treatments, and losing quality of life. Any test that could cut that wait — even by a few years — would be a genuine medical advance. That context is why each new “breakthrough” announcement draws so much hope, and why the details behind the numbers matter so much.

What the New Study Actually Found

Researchers analyzed blood samples from 159 women — some with endometriosis, some without. They found that women with the condition shared a distinct hormonal fingerprint. Specifically, they showed elevated levels of certain androgens, including 11-ketotestosterone. Based on that hormonal pattern, the team said they could correctly identify which patients had endometriosis and which did not with more than 95% accuracy. The research team is now looking for industry partners to turn these findings into a usable diagnostic blood test.

The Number That Deserves a Closer Look

Here is where the story gets more complicated. The media reports cite “over 95% accuracy” but do not break that number down into sensitivity and specificity — the two measures that actually tell you how useful a test is in the real world. Sensitivity tells you how often the test catches real cases. Specificity tells you how often it correctly clears people who do not have the disease. A test can score very high on one while failing badly on the other. Without those numbers from this specific study, the 95% figure is hard to evaluate.

Other Blood Tests Are Already on the Market — With Mixed Results

HerAnova Lifesciences launched its HerResolve test commercially in December 2025. A validation study showed it achieved a specificity of 97.5% but a sensitivity of only 80%. That means it correctly cleared most women who did not have endometriosis, but it missed one in five women who did. Separately, HerResolve did identify 61.5% of confirmed endometriosis cases that standard imaging had already missed — which is genuinely useful. Another test called EndomTest by Kephera Diagnostics showed even lower sensitivity at 46.2%, meaning it missed more than half of actual cases.

Women with endometriosis have a distinct pattern of androgens in their blood that sets them apart from women without the disease, based on a recent case-control study.

These findings could lead to a noninvasive test for a condition that often takes years to diagnose and… pic.twitter.com/Z681iD2Zkm

— Medscape (@Medscape) July 14, 2026

These are not minor technical footnotes. A test with low sensitivity gives women a false sense of reassurance. They walk away thinking they are fine when they are not. For a condition already defined by years of being dismissed, that outcome would make things worse, not better. The European Society of Human Reproduction and Embryology (ESHRE) 2022 clinical guidelines state plainly that clinicians should not use blood biomarkers to diagnose endometriosis, citing the lack of any marker that can reliably rule the condition in or out.

A Pattern Worth Recognizing Before Celebrating

This is not the first time a blood test for endometriosis has made headlines with impressive accuracy numbers. A 2016 Cochrane review examined 27 studies covering more than 3,400 women and found that none of the biomarkers tested met the criteria needed for clinical use. That review included tests that initially looked promising. The new hormone-pattern study may genuinely be different — the androgen finding is specific and biologically plausible. But it has not yet been independently replicated in a larger, more diverse group of patients, and the full peer-reviewed methodology has not been published with the detail needed to verify the claim.

What Would Actually Change Everything

The path from “promising study” to “doctor’s office blood draw” is long. Researchers need to publish the full methodology with sensitivity and specificity breakdowns. An independent team needs to replicate the results in at least 500 patients across different demographics and disease stages. Regulators need to review the data. None of that has happened yet for this specific test. The 95% figure may hold up — or it may narrow considerably once the full picture is examined. Women deserve to know the difference between a result that looks good in a lab and one that holds up in a clinic. The hope here is real. So is the need for patience.